CD3-HM430-100μg / 詢價(jià)
CD3-HM430-500μg / 詢價(jià)
CD3-HM430-500μgx2 / 詢價(jià)
- 關(guān)聯(lián)產(chǎn)品
- 客服電話
- 技術(shù)支持
Non-biotinylated Human CD30/TNFRSF8 Protein
Recombinant Human CD30/TNFRSF8 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Phe19-Lys379 [Accession | P28908-1].
The protein has a predicted MW of 41.3 kDa. Due to glycosylation, the protein migrates to 68-95 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 90% as determined by HPLC
Less than 1 EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs).
CD30; CD30KI-1; CD30L receptor; TNFRSF8; D1S166EKi-1; CD30KI-1
(1) Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol. 2009;647:174-85. doi: 10.1007/978-0-387-89520-8_12. PMID: 19760074.
.png)